Edition:
Deutschland

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

89.90USD
22:02 Uhr
Change (% chg)

$-2.37 (-2.57%)
Prev Close
$92.27
Open
$91.85
Day's High
$92.40
Day's Low
$89.23
Volume
1,230,503
Avg. Vol
1,542,767
52-wk High
$125.84
52-wk Low
$85.30

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Buy/Sell

Sell Hold Buy
2.45 Mean rating from 20 analysts

Overall

Beta: 1.53
Market Cap(Mil.): $144,249.59
Shares Outstanding(Mil.): 1,594.09
Dividend: 0.64
Yield (%): 2.83

Samsung launches third rival to AbbVie's Humira drug in EU

LONDON South Korea's Samsung Bioepis and its partner Biogen have launched a third rival to AbbVie's blockbuster medicine Humira in Europe, ramping up competition for a slice of the world's top-selling prescription drug's sales.

Samsung launches third rival to AbbVie's Humira drug in EU

LONDON, Oct 17 South Korea's Samsung Bioepis and its partner Biogen have launched a third rival to AbbVie's blockbuster medicine Humira in Europe, ramping up competition for a slice of the world's top-selling prescription drug's sales.

PRESS DIGEST -Wall Street Journal - Oct 17

Oct 17 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU

LONDON, Oct 16 Rival versions of the world’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States.

BRIEF-Sandoz Launches Biosimilar Version Of Abbvie's Humira In UK

* NOVARTIS UNIT SANDOZ LAUNCHES HYRIMOZ, ITS BIOSIMILAR VERSION OF ABBVIE'S HUMIRA, IN UK AS OF OCT 16; OTHER EUROPEAN MARKETS TO FOLLOW -SPOKESMAN Further company coverage: (Reporting by UK bureau)

Photo

U.S. to propose TV ads for drugs must include list prices

The U.S. government, in an effort to increase pressure on drugmakers to lower costs for U.S. consumers, said on Monday it will propose requiring companies to include the price of their prescription medicines in television ads.

UPDATE 1-U.S. to propose TV ads for drugs must include list prices

Oct 15 The U.S. government, in an effort to increase pressure on drugmakers to lower costs for U.S. consumers, said on Monday it will propose requiring companies to include the price of their prescription medicines in television ads.

U.S. TV drug ads to carry information on prices

Oct 15 TV advertisements for drugs made by major U.S. companies will soon direct patients to information about the potential price of medicines, a pharmaceutical industry lobbying group said https://www.phrma.org/press-release/phrma-members-take-new-approach-to-dtc-television-advertising on Monday.

Swiss stocks - Factors to watch on Oct. 12

ZURICH/BERLIN, Oct 12 The Swiss blue-chip SMI was seen opening 0.9 percent higher at 8,718 points on Friday, according to premarket indications by bank Julius Baer .

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -1.28%
Rohstoffe -1.53%
Industrie -1.37%
Konjunktur abhängige Waren & Dienstleistungen -0.32%
Konjunktur unabhängige Waren & Dienstleistungen -1.09%
Finanzindustrie -0.92%
Pharma -2.21%
Technologie +0.19%
Telekommunikation +0.02%